| Unique ID issued by UMIN | UMIN000054142 |
|---|---|
| Receipt number | R000061823 |
| Scientific Title | Clinical Study on Dotinurad for Hyperuricemia |
| Date of disclosure of the study information | 2024/04/13 |
| Last modified on | 2025/04/07 11:44:44 |
Clinical Study on Dotinurad for Hyperuricemia
Clinical Study on Dotinurad for Hyperuricemia
Clinical Study on Dotinurad for Hyperuricemia
Clinical Study on Dotinurad for Hyperuricemia
| Japan |
Hyperuricemic patients with uric acid levels of 8.0 mg/dL or higher
| Medicine in general | Endocrinology and Metabolism |
Others
NO
Observe the effectiveness of Dothinurad
Safety,Efficacy
uric acid
1) BUN, Cr, eGFR
2) Cystatin C
3) Oxidized LDL, high sensitivity CRP
4) Albuminuria
5) Side effects
Observational
| 20 | years-old | <= |
| 90 | years-old | >= |
Male and Female
Hyperuricemia with uric acid level of 7.0 or higher
Patients who were deemed not appropriate to participate in this study by doctor
50
| 1st name | Akira |
| Middle name | |
| Last name | Sezai |
Nihon University School of Medicine
Department of Cardiovascular Surgery
1738610
30-1 Oyaguchi kami-machi, Itabashi-ku, Tokyo, Japan
03-3972-8111
asezai.med@gmail.com
| 1st name | Mitsue |
| Middle name | |
| Last name | Akiyama |
Sekino Laboratory
Department of Research
1710014
3-28-3 Ikebukuro, Toshima-ku, Tokyo, Japan
03-3986-5501
skn-np@sekino-hospital.com
Sekino Hospital
self funding
Self funding
Sekino Laboratory
3-28-3 Ikebukuro, Toshima-ku, Tokyo, Japan
03-3986-5501
skn-np@sekino-hospital.com
NO
関野病院(東京都)
| 2024 | Year | 04 | Month | 13 | Day |
Unpublished
Enrolling by invitation
| 2024 | Year | 02 | Month | 15 | Day |
| 2024 | Year | 03 | Month | 05 | Day |
| 2024 | Year | 03 | Month | 16 | Day |
| 2025 | Year | 12 | Month | 31 | Day |
Observation for 6 months
| 2024 | Year | 04 | Month | 13 | Day |
| 2025 | Year | 04 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061823